Translation initiation factor eIF4F modifies the dexamethasone response in multiple myeloma

eIF4 Initiation Factors: Effectors of mRNA Recruitment to Ribosomes and Regulators of Translation

Gingras, A., Raught, B., & Sonenberg, N. (1999) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.68.1.913 · Cited by 2,103 · see citing works

Initial genome sequencing and analysis of multiple myeloma

Chapman, M. A., Lawrence, M. S., Keats, J. J., Cibulskis, K., Sougnez, C. L., Schinzel, A. C., Harview, C. L., Brunet, J.-P., Ahmann, G. J., Adli, M., et al. (2011) · Nature · doi:10.1038/nature09837 · Cited by 1,422 · see citing works

DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival

Peterson, T. R., Laplante, M., Thoreen, C. C., Sancak, Y., Kang, S. A., Kuehl, W. M., Gray, N. S., & Sabatini, D. M. (2009) · Cell · doi:10.1016/j.cell.2009.03.046 · Cited by 1,202 · see citing works

Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy

Wendel, H., de Stanchina, E., Fridman, J. S., Malina, A., Ray, S., Kogan, S. C., Cordon‐Cardo, C., Pelletier, J., & Lowe, S. W. (2004) · Nature · doi:10.1038/nature02369 · Cited by 956 · see citing works

eIF-4E expression and its role in malignancies and metastases

Benedetti, A. D., & Graff, J. R. (2004) · Oncogene · doi:10.1038/sj.onc.1207545 · Cited by 728 · see citing works

Dissecting eIF4E action in tumorigenesis.Preprint

Wendel, H., Silva, R. L. A., Malina, A., Mills, J., Zhu, H., Ueda, T., Watanabe‐Fukunaga, R., Fukunaga, R., Teruya-Feldstein, J., Pelletier, J., et al. (2007) · Genes & Development · doi:10.1101/gad.1604407 · Cited by 512 · see citing works

Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance

Wei, G., Twomey, D., Lamb, J., Schlis, K. D., Agarwal, J., Stam, R. W., Opferman, J. T., Sallan, S. E., den Boer, M. L., Pieters, R., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.09.006 · Cited by 505 · see citing works

A new dexamethasone-induced gene of the leucine zipper family protects T lymphocytes from TCR/CD3-activated cell death

D'Adamio, F., Zollo, O., Moraca, R., Ayroldi, E., Bruscoli, S., Bartoli, A., Cannarile, L., Migliorati, G., & Riccardi, C. (1997) · Immunity · doi:10.1016/s1074-7613(00)80398-2 · Cited by 444 · see citing works

Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma.

Shou, Y., Martelli, M., Gabrea, A., Qi, Y., Brents, L., Roschke, A., Dewald, G., Kirsch, I., Bergsagel, P., & Kuehl, W. (2000) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.97.1.228 · Cited by 356 · see citing works

Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival

Wuillème‐Toumi, S., Robillard, N., Gomez‐Bougie, P., Moreau, P., Gouill, S. L., Avet‐Loiseau, H., Harousseau, J., Amiot, M., & Bataille, R. (2005) · Leukemia · doi:10.1038/sj.leu.2403784 · Cited by 337 · see citing works

Targeting the Eukaryotic Translation Initiation Factor 4E for Cancer Therapy

Graff, J. R., Konicek, B. W., Carter, J. H., & Marcusson, E. G. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5635 · Cited by 333 · see citing works

Antitumor Activity and Mechanism of Action of the Cyclopenta[b]benzofuran, Silvestrol

Cencic, R., Carrier, M., Galicia-Vázquez, G., Bordeleau, M.-E., Sukarieh, R., Bourdeau, A., Brem, B., Teodoro, J. G., Greger, H., Tremblay, M. L., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005223 · Cited by 302 · see citing works

A Novel Functional Human Eukaryotic Translation Initiation Factor 4G

Gradi, A., Imataka, H., Svitkin, Y. V., Rom, E., Raught, B., Morino, S., & Sonenberg, N. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.1.334 · Cited by 296 · see citing works

Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers

Pourdehnad, M., Truitt, M., Siddiqi, I. N., Ducker, G. S., Shokat, K. M., & Ruggero, D. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1310230110 · Cited by 288 · see citing works

Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma

Chng, W.-J., Huang, G. F., Chung, T., Ng, S., Gonzalez-Paz, N. C., Troska-Price, T., Mulligan, G., Chesi, M., Bergsagel, P. L., & Fonseca, R. (2011) · Leukemia · doi:10.1038/leu.2011.53 · Cited by 272 · see citing works

Increased expression of eukaryotic translation initiation factors eIF-4E and eIF-2 alpha in response to growth induction by c-myc.

Rosenwald, I. B., Rhoads, D. B., Callanan, L., Isselbacher, K. J., & Schmidt, E. V. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.13.6175 · Cited by 256 · see citing works

PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis

Ilić, N., Utermark, T., Widlund, H. R., & Roberts, T. M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108237108 · Cited by 213 · see citing works

Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis

Kanungo, A., Medeiros, L. J., Abruzzo, L. V., & Lin, P. (2005) · Modern Pathology · doi:10.1038/modpathol.3800500 · Cited by 208 · see citing works

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma

Raje, N. S., Kumar, S. K., Hideshima, T., Ishitsuka, K., Chauhan, D., Mitsiades, C. S., Podar, K., Gouill, S. L., Richardson, P. G. G., Munshi, N. C., et al. (2004) · Blood · doi:10.1182/blood-2004-06-2281 · Cited by 186 · see citing works

c-Myc and eIF4F Are Components of a Feedforward Loop that Links Transcription and Translation

Lin, C.-J., Cencic, R., Mills, J. R., Robert, F., & Pelletier, J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5876 · Cited by 180 · see citing works

Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone

Strömberg, T., Dimberg, A., Hammarberg, A., Carlson, K. E., Österborg, A., Nilsson, K., & Jernberg‐Wiklund, H. (2003) · Blood · doi:10.1182/blood-2003-05-1543 · Cited by 154 · see citing works

Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235

McMillin, D. W., Ooi, M. G. M., Delmore, J. E., Negri, J. M., Hayden, P. J., Mitsiades, N., Jakubı́ková, J., Maira, S.-M., Garcı́a-Echeverrı́a, C., Schlossman, R. L., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4285 · Cited by 124 · see citing works

A cellular response linking eIF4AI activity to eIF4AII transcription

Galicia-Vázquez, G., Cencic, R., Robert, F., Agenor, A., & Pelletier, J. (2012) · RNA · doi:10.1261/rna.033209.112 · Cited by 119 · see citing works

Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor

Hoang, B. Q., Frost, P., Shi, Y., Belanger, E., Benavides, A., Pezeshkpour, G. H., Cappia, S., Guglielmelli, T., Gera, J., & Lichtenstein, A. K. (2010) · Blood · doi:10.1182/blood-2010-05-285726 · Cited by 117 · see citing works

Mechanism by Which Mammalian Target of Rapamycin Inhibitors Sensitize Multiple Myeloma Cells to Dexamethasone-Induced Apoptosis

Yan, H., Frost, P., Shi, Y., Hoang, B. Q., Sharma, S., Fisher, M., Gera, J., & Lichtenstein, A. K. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2447 · Cited by 108 · see citing works

Pathologic human GR mutant has a transdominant negative effect on the wild-type GR by inhibiting its translocation into the nucleus: importance of the ligand-binding domain for intracellular GR trafficking

Kino, T., Stauber, R. H., Resau, J. H., Pavlakis, G. N., & Chrousos, G. P. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.11.8017 · Cited by 105 · see citing works

Synthetic Silvestrol Analogues as Potent and Selective Protein Synthesis Inhibitors

Liu, T., Nair, S. J., Lescarbeau, A., Belani, J. D., Peluso, S., Conley, J., Tillotson, B. P., O’Hearn, P. J., Smith, S. A., Slocum, K. L., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3011542 · Cited by 86 · see citing works

Analysis for microsatellite instability and mutations of the DNA mismatch repair gene hMLH1 in familial gastric cancer

Keller, G., Grimm, V., Vogelsang, H., Bischoff, P., Mueller, J., Siewert, J. R., & Höfler, H. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19961127)68:5 · Cited by 76 · see citing works

Emerging Therapeutics Targeting mRNA TranslationPreprint

Malina, A., Mills, J. R., & Pelletier, J. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012377 · Cited by 65 · see citing works

The cap-translation inhibitor 4EGI-1 induces apoptosis in multiple myeloma through Noxa induction

Descamps, G., Gomez‐Bougie, P., Tamburini, J., Green, A. S., Bouscary, D., Maïga, S., Moreau, P., Gouill, S. L., Pellat‐Deceunynck, C., & Amiot, M. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.139 · Cited by 58 · see citing works

Glucocorticoid receptor transcriptional isoforms and resistance in multiple myeloma cells

Sánchez-Vega, B., Krett, N. L., Rosen, S. T., & Gandhi, V. V. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0344 · Cited by 44 · see citing works

IL-6-independent expression of Mcl-1 in human multiple myeloma

Zhang, B., Potyagaylo, V., & Fenton, R. G. (2003) · Oncogene · doi:10.1038/sj.onc.1206358 · Cited by 39 · see citing works

The mammalian target of rapamycin pathway as a therapeutic target in multiple myeloma

Gera, J., & Lichtenstein, A. K. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.580478 · Cited by 36 · see citing works

Glucocorticoid Receptors and Glucocorticoid Resistance in Human Leukemia in Vivo and in Vitro

Thompson, E. B., & Harmon, J. M. (1986) · Advances in experimental medicine and biology · doi:10.1007/978-1-4684-5101-6_8 · Cited by 33 · see citing works

How myeloma cells escape bisphosphonate‐mediated killing: development of specific resistance with preserved sensitivity to conventional chemotherapeutics

Salomo, M., Jurlander, J., Nielsen, L. B., & Gimsing, P. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04437.x · Cited by 26 · see citing works

Multiple Myeloma: Biology, Standard Therapy, and Transplant Therapy

Gertz, M. A., Ghobrial, I. M., & Luc-Harousseau, J. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.10.006 · Cited by 7 · see citing works

Targeting the eIF4F Translation Initiation Complex: A Critical Nexus for Cancer Development

Pelletier, J., Graff, J., Ruggero, D., & Sonenberg, N. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2789 · Cited by 367 · see citing works

The biology of DHX9 and its potential as a therapeutic target

Lee, T., & Pelletier, J. (2016) · Oncotarget · doi:10.18632/oncotarget.8446 · Cited by 190 · see citing works

ERα is an RNA-binding protein sustaining tumor cell survival and drug resistance

Xu, Y., Huangyang, P., Wang, Y., Xue, L., Devericks, E. N., Nguyen, H. G., Yu, X., Osés-Prieto, J. A., Burlingame, A. L., Miglani, S., et al. (2021) · Cell · doi:10.1016/j.cell.2021.08.036 · Cited by 166 · see citing works

CUG initiation and frameshifting enable production of dipeptide repeat proteins from ALS/FTD C9ORF72 transcripts

Tabet, R., Schaeffer, L., Freyermuth, F., Jambeau, M., Workman, M. J., Lee, C.-Z., Lin, C.-C., Jiang, J., Jansen‐West, K. R., Abou‐Hamdan, H., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02643-5 · Cited by 143 · see citing works

Translation Initiation Factors: Reprogramming Protein Synthesis in Cancer

Chu, J., Cargnello, M., Topisirović, I., & Pelletier, J. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2016.06.005 · Cited by 127 · see citing works

Glucocorticoids in multiple myeloma: past, present, and future

Burwick, N. R., & Sharma, S. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3465-8 · Cited by 111 · see citing works

CRISPR-Mediated Drug-Target Validation Reveals Selective Pharmacological Inhibition of the RNA Helicase, eIF4A

Chu, J., Galicia-Vázquez, G., Cencic, R., Mills, J. R., Katigbak, A., Porco, J. A. J., & Pelletier, J. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.005 · Cited by 100 · see citing works

Targeting RNA helicases in cancer: The translation trap

van Voss, M. R. H., van Diest, P. J., & Raman, V. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.09.006 · Cited by 87 · see citing works

Amidino-Rocaglates: A Potent Class of eIF4A Inhibitors

Chu, J., Zhang, W., Cencic, R., Devine, W. G., Beglov, D., Henkel, T., Brown, L. E., Vajda, S., Porco, J. A., & Pelletier, J. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.08.008 · Cited by 74 · see citing works

eIF4A2 drives repression of translation at initiation by Ccr4-Not through purine-rich motifs in the 5′UTR

Wilczynska, A., Gillen, S. L., Schmidt, T., Meijer, H. A., Jukes‐Jones, R., Langlais, C., Kopra, K., Lu, W.-T., Godfrey, J. D., Hawley, B. R., et al. (2019) · Genome biology · doi:10.1186/s13059-019-1857-2 · Cited by 72 · see citing works

Hippuristanol - A potent steroid inhibitor of eukaryotic initiation factor 4A

Cencic, R., & Pelletier, J. (2016) · Translation · doi:10.1080/21690731.2015.1137381 · Cited by 63 · see citing works

Tumor cell survival dependence on the DHX9 DExH-box helicase

Lee, T., Paquet, M., Larsson, O. S., & Pelletier, J. (2016) · Oncogene · doi:10.1038/onc.2016.52 · Cited by 61 · see citing works

Repression of p53-target gene Bbc3/PUMA by MYSM1 is essential for the survival of hematopoietic multipotent progenitors and contributes to stem cell maintenance

Belle, J. I., Petrov, J. C., Langlais, D., Robert, F., Cencic, R., Shen, S., Pelletier, J., Gros, P., & Nijnik, A. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2015.140 · Cited by 58 · see citing works

mRNA structural elements immediately upstream of the start codon dictate dependence upon eIF4A helicase activity

Waldron, J. A., Tack, D. C., Ritchey, L. E., Gillen, S. L., Wilczynska, A., Turro, E., Bevilacqua, P. C., Assmann, S. M., Bushell, M., & Quesne, J. P. C. L. (2019) · Genome biology · doi:10.1186/s13059-019-1901-2 · Cited by 56 · see citing works

Selective targeting of the DEAD-box RNA helicase eukaryotic initiation factor (eIF) 4A by natural products

Shen, L. L., & Pelletier, J. (2019) · Natural Product Reports · doi:10.1039/c9np00052f · Cited by 53 · see citing works

eIF4A Inhibitors Suppress Cell-Cycle Feedback Response and Acquired Resistance to CDK4/6 Inhibition in Cancer

Kong, T., Xue, Y., Cencic, R., Zhu, X., Monast, A., Fu, Z., Pilon, V., Sangwan, V., Guiot, M., Foulkes, W. D., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0162 · Cited by 46 · see citing works

eIF4A alleviates the translational repression mediated by classical secondary structures more than by G-quadruplexes

Waldron, J. A., Raza, F., & Quesne, J. P. C. L. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky108 · Cited by 44 · see citing works

Latest perspectives on glucocorticoid-induced apoptosis and resistance in lymphoid malignancies

Clarisse, D., Offner, F. C., & Bosscher, K. D. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188430 · Cited by 45 · see citing works

Therapeutic Opportunities in Eukaryotic TranslationPreprint

Chu, J., & Pelletier, J. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a032995 · Cited by 40 · see citing works

The role of eIF4F-driven mRNA translation in regulating the tumour microenvironment

Bartish, M., Abraham, M. J., Gonçalves, C., Larsson, O. S., Rolny, C., & Rincon, S. V. D. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00567-5 · Cited by 39 · see citing works

A comparative study of small molecules targeting eIF4A

Naineni, S. K., Maïga, R. I., Cencic, R., Putnam, A. A., Amador, L. A., Rodrı́guez, A. D., Jankowsky, E., & Pelletier, J. (2020) · RNA · doi:10.1261/rna.072884.119 · Cited by 38 · see citing works

The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple Myeloma

Paradžik, T., Bandini, C., Mereu, E., Labrador, M., Taìana, E., Amodio, N., Neri, A., & Piva, R. (2021) · Cancers · doi:10.3390/cancers13061235 · Cited by 36 · see citing works

Chemical Synthesis Enables Structural Reengineering of Aglaroxin C Leading to Inhibition Bias for Hepatitis C Viral Infection

Zhang, W., Liu, S., Maïga, R. I., Pelletier, J., Brown, L. E., Wang, T. T., & Porco, J. A. J. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b11477 · Cited by 35 · see citing works

Eukaryotic Translation Initiation Factor 3b is both a Promising Prognostic Biomarker and a Potential Therapeutic Target for Patients with Clear Cell Renal Cell Carcinoma

Zang, Y., Zhang, X., Yan, L., Gu, G., Li, D., Zhang, Y., Fang, L., Fu, S., Ren, J., & Xu, Z. (2017) · Journal of Cancer · doi:10.7150/jca.19594 · Cited by 34 · see citing works

Targeting translation initiation by synthetic rocaglates for treating MYC-driven lymphomas

Zhang, X., Bi, C., Lu, T., Zhang, W., Yue, T., Wang, C., Tian, T., Zhang, X., Huang, Y., Lunning, M. A., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0503-z · Cited by 34 · see citing works

NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy

Sanghvi, V. R., Mohan, P., Singh, K., Cao, L., Berishaj, M., Wolfe, A. L., Schatz, J. H., Lailler, N., de Stanchina, E., Viale, A., et al. (2021) · Cancers · doi:10.3390/cancers13040639 · Cited by 27 · see citing works

Targeting mTOR signaling pathways in multiple myeloma: biology and implication for therapy

Wang, Y.-M., Vandewalle, N., Veirman, K. D., Vanderkerken, K., Menu, E., & Bruyne, E. D. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01699-3 · Cited by 29 · see citing works

Natural products as drugs and tools for influencing core processes of eukaryotic mRNA translation

Burgers, L. D., & Fürst, R. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105535 · Cited by 29 · see citing works

Translation Inhibition by Rocaglates Is Independent of eIF4E Phosphorylation Status

Chu, J., Cencic, R., Wang, W., Porco, J. A. J., & Pelletier, J. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0409 · Cited by 25 · see citing works

YWHAE/14-3-3ε expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma

Xu, Y., Fulciniti, M., Samur, M., Ho, M., Deng, S., Liu, L., Wen, K., Yu, T., Chyra, Z., Dereibal, S., et al. (2020) · Blood · doi:10.1182/blood.2019004147 · Cited by 23 · see citing works

Identification of novel leishmanicidal molecules by virtual and biochemical screenings targeting Leishmania eukaryotic translation initiation factor 4A

Harigua‐Souiai, E., Abdelkrim, Y. Z., Bassoumi-Jamoussi, I., Zakraoui, O., Bouvier, G., Essafi‐Benkhadir, K., Banroques, J., Desdouits, N., Munier‐Lehmann, H., Barhoumi, M., et al. (2018) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0006160 · Cited by 22 · see citing works

Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer

Garrido, M. F., Martin, N. J.-P., Bertrand, M., Gaudin, C., Commo, F., Kalaany, N. E., Nakouzi, N. A., Fazli, L., Nery, E. D., Camonis, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0704 · Cited by 21 · see citing works

Assessing eukaryotic initiation factor 4F subunit essentiality by CRISPR-induced gene ablation in the mouse

Sénéchal, P., Robert, F., Cencic, R., Yanagiya, A., Chu, J., Sonenberg, N., Paquet, M., & Pelletier, J. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03940-5 · Cited by 20 · see citing works

Inducible Genome Editing with Conditional CRISPR/Cas9 Mice

Katigbak, A., Robert, F., Paquet, M., & Pelletier, J. (2018) · G3 Genes Genomes Genetics · doi:10.1534/g3.117.300327 · Cited by 20 · see citing works

RNA interference for multiple myeloma therapy: targeting signal transduction pathways

Guo, J., McKenna, S. L., O'Dwyer, M. E., Cahill, M. R., & O’Driscoll, C. M. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2015.1071355 · Cited by 17 · see citing works

Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma

Sriskandarajah, P., Brandon, A. D. H., Macleod, K., Carragher, N. O., Kirkin, V., Kaiser, M., & Whittaker, S. R. (2020) · BMC Cancer · doi:10.1186/s12885-020-06735-2 · Cited by 14 · see citing works

Eukaryotic Translation Initiation Factor 4AI: A Potential Novel Target in Neuroblastoma

Skofler, C., Kleinegger, F., Krassnig, S., Birkl-Toeglhofer, A. M., Singer, G., Till, H., Benesch, M., Cencic, R., Porco, J. A. J., Pelletier, J., et al. (2021) · Cells · doi:10.3390/cells10020301 · Cited by 15 · see citing works

Targeting the N Terminus of eIF4AI for Inhibition of Its Catalytic Recycling

Jiang, C., Tang, Y., Ding, L., Tan, R., Li, X., Lu, J., Jiang, J., Cui, Z., Tang, Z., Li, W., et al. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.07.010 · Cited by 15 · see citing works

Protein tyrosine phosphatome metabolic screen identifies TC‐PTP as a positive regulator of cancer cell bioenergetics and mitochondrial dynamics

Vinette, V., Aubry, I., Insull, H., Uetani, N., Hardy, S., & Tremblay, M. L. (2021) · The FASEB Journal · doi:10.1096/fj.202100207r · Cited by 11 · see citing works

Therapeutic targeting of eukaryotic initiation factor (eIF) 4E

Pelletier, J., & Sonenberg, N. (2023) · Biochemical Society Transactions · doi:10.1042/bst20220285 · Cited by 11 · see citing works

Developing anti-neoplastic biotherapeutics against eIF4F

Steinberger, J., Chu, J., Maïga, R. I., Sleiman, K., & Pelletier, J. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2430-8 · Cited by 11 · see citing works

Silvestrol, a potent anticancer agent with unfavourable pharmacokinetics: Current knowledge on its pharmacological properties and future directions for the development of novel drugs

Peron, G., Mastinu, A., Peña‐Corona, S. I., Hernández‐Parra, H., Leyva‐Gómez, G., Călina, D. C., & Sharifi‐Rad, J. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117047 · Cited by 11 · see citing works

Deletion of eIF2β lysine stretches creates a dominant negative that affects the translation and proliferation in human cell line: A tool for arresting the cell growth

Salton, G. D., Laurino, C. C. F. C., Mega, N. O., Cañedo, A. D., Setterblad, N., Carmagnat, M., Xavier, R. M., Lima, E. O. C., Lenz, G., Henriques, J. A. P., et al. (2017) · Cancer Biology & Therapy · doi:10.1080/15384047.2017.1345383 · Cited by 11 · see citing works

Oxo-aglaiastatin-Mediated Inhibition of Translation Initiation

Maïga, R. I., Cencic, R., Chu, J., Waller, D. D., Brown, L. E., Devine, W. G., Zhang, W., Sébag, M., Porco, J. A. J., & Pelletier, J. (2019) · Scientific Reports · doi:10.1038/s41598-018-37666-5 · Cited by 10 · see citing works

Tracing MYC Expression for Small Molecule Discovery

Steinberger, J., Robert, F., Hallé, M., Williams, D. E., Cencic, R., Sawhney, N., Pelletier, D., Williams, P. G., Igarashi, Y., Porco, J. A. J., et al. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.02.007 · Cited by 11 · see citing works

The role of RNA binding proteins in cancer biology: A focus on FMRP

Jia, Y., Jia, R., Chen, Y., Lin, X., Aishan, N., Li, H., Wang, L., Zhang, X., & Ruan, J. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101493 · Cited by 7 · see citing works

Aptamers, a New Therapeutic Opportunity for the Treatment of Multiple Myeloma

Amundarain, A., Pastor, F., Prósper, F., & Agirre, X. (2022) · Cancers · doi:10.3390/cancers14215471 · Cited by 6 · see citing works

Scaffolds and Biological Targets Avenue to Fight Against Drug Resistance in Leishmaniasis

Borsari, C., Quotadamo, A., Ferrari, S., Venturelli, A., Cordeiro‐da‐Silva, A., Santarém, N., & Costi, M. P. (2018) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2018.08.002 · Cited by 6 · see citing works

TACIMA-218: A Novel Pro-Oxidant Agent Exhibiting Selective Antitumoral Activity

Abusarah, J., Cui, Y., El-Hachem, N., El-Kadiry, A. E.-H., Hammond-Martel, I., Würtele, H., Beaudry, A., Raynal, N. J. ‐., Robert, F., Pelletier, J., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0333 · Cited by 5 · see citing works

The ribosome-inactivating proteins MAP30 and Momordin inhibit SARS-CoV-2

Watts, N. R. M., Eren, E., Palmer, I. W., Huang, P. L., Huang, P. L., Shoemaker, R. H., Lee‐Huang, S., & Wingfield, P. T. (2023) · PLoS ONE · doi:10.1371/journal.pone.0286370 · Cited by 5 · see citing works

Proteomic Analysis of Bone Marrow CD138+ Cells to Identify Proteins Associated With the Response of Multiple Myeloma Patients to Commonly Used Therapeutic Regimens

Paradeisi, F., Tserga, A., Lygirou, V., Makridakis, M., Stroggilos, R., Georgiou, G., Spyrou, G. M., Kostopoulos, I. V., Liacos, C., Termentzi, A., et al. (2025) · PROTEOMICS · doi:10.1002/pmic.70025 · Cited by 2 · see citing works

eIF4A1 is essential for reprogramming the translational landscape of Wnt-driven colorectal cancersPreprint

Waldron, J. A., Kanellos, G., Smith, R. C. L., Knight, J. R. P., Munro, J., Alexandrou, C., Vlahov, N., Pardo, L., Moore, M. H., Gillen, S. L., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.10.566546 · Cited by 2 · see citing works

Necrotic Cells Alter IRE1α-XBP1 Signaling and Induce Transcriptional Changes in Glioblastoma

Lim, J., Lee, S., Hong, Y.-S., Choi, J. H., Jo, A., Kang, J. L., Song, T., & Choi, Y.-H. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27010474 · Cited by 1 · see citing works

Targeting metabolic reprogramming in multiple myeloma: Molecular mechanisms and potential therapeutic targets

Zhu, X., Wang, Y., He, Y., Li, Y., Wang, C., Zeng, R., Ouyang, Q., Su, C., Hu, Q., Lu, G., et al. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105257 · Cited by 1 · see citing works

PTPN1/PTPN2 inhibition improves NK cancer therapy by enhancing IL-2 and mitigating TGFβ1 responses

Feng, C.-H., Peltier, L., Chouleur, T., DiPonzio, M., Aubry, I., Poirier, A. J., Córdova, Z. M., Shen, Y., Tabariès, S., Cao, X., et al. (2026) · EMBO Reports · doi:10.1038/s44319-026-00745-0 · Cited by 1 · see citing works

Canada's contributions to RNA research: past, present, and future perspectives

Lécuyer, É., Sauvageau, M., Kothe, U., Unrau, P. J., Damha, M. J., Perreault, J., Elela, S. A., Bayfield, M. A., Claycomb, J. M., & Scott, M. S. (2024) · Biochemistry and Cell Biology · doi:10.1139/bcb-2024-0176 · Cited by 1 · see citing works

Targeting eIF4F in cancer

Yi, T. (2016) · Journal of Pharmaceutical and Pharmacological Sciences · doi:10.29011/2574-7711.100002

CUG initiation and frameshifting enable production of dipeptide repeat proteins from ALS/FTD C9ORF72 transcripts

Martin, F. (2020) · doi:10.26226/morressier.5ebd45acffea6f735881aeef

Data from TACIMA-218: A Novel Pro-Oxidant Agent Exhibiting Selective Antitumoral Activity

Abusarah, J., Cui, Y., El-Hachem, N., El-Kadiry, A. E.-H., Hammond-Martel, I., Würtele, H., Beaudry, A., Raynal, N. J. ‐., Robert, F., Pelletier, J., et al. (2023) · doi:10.1158/1535-7163.c.6542889

LncRNAs: Novel therapeutic targets to treat Multiple Myeloma with RNA-based therapies

Amundarain, A. (2023) · doi:10.15581/10171/67866 · Cited by 2 · see citing works

Additional file 2 of Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma

Sriskandarajah, P., de Haven‐Brandon, A., Macleod, K., Carragher, N. O., Kirkin, V., Kaiser, M., & Whittaker, S. R. (2020) · Figshare · doi:10.6084/m9.figshare.12050775

Additional file 1 of Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma

Sriskandarajah, P., de Haven‐Brandon, A., Macleod, K., Carragher, N. O., Kirkin, V., Kaiser, M., & Whittaker, S. R. (2020) · Figshare · doi:10.6084/m9.figshare.12050766

Synthèse de nouveaux agents anticancéreux

Abou‐Hamdan, H. (2018) · doi:10.70675/9195b726z7245z42f8za28cz127953446494

Translating Translation: Lessons from Zotatifin’s Clinical Development and the Case for Trials in Lymphoma

Manara, P., & Schatz, J. H. (2026) · Current Oncology Reports · doi:10.1007/s11912-026-01848-6

Eukaryotic translation initiation factor 4F (eIF4F)

(2014) · Science-Business eXchange · doi:10.1038/scibx.2014.1122

The Translation Initiation Factor eIF4E Is Overexpressed in Multiple Myeloma and Is Critical for Myeloma Cell Proliferation and Survival

Li, S., Jin, M., Liu, A., Mapara, M. Y., & Lentzsch, S. (2011) · Blood · doi:10.1182/blood.v118.21.1853.1853 · Cited by 2 · see citing works

The eIF2-alpha kinase HRI is a novel therapeutic target in multiple myeloma

Burwick, N. R., Zhang, M. Y., de la Puente, P., Azab, A. K., Hyun, T. S., Ruiz‐Gutierrez, M., Sánchez-Bonilla, M., Nakamura, T., Delrow, J. J., MacKay, V. L., et al. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.01.007 · Cited by 31 · see citing works

Elevated Translation Initiation Factor eIF4E Is an Attractive Therapeutic Target in Multiple Myeloma

Li, S., Fu, J., Lu, C., Mapara, M. Y., Raza, S., Hengst, U., & Lentzsch, S. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0798 · Cited by 23 · see citing works

Cap-Dependent Protein Translation Initiation in Multiple Myeloma: An Attractive Target for Therapy

Li, S., Fu, J., & Lentzsch, S. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4660-6_3 · Cited by 2 · see citing works